Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBITDA (2020 - 2025)

Rani Therapeutics Holdings has reported EBITDA over the past 6 years, most recently at -$8.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$8.5 million for Q4 2025, up 42.94% from a year ago — trailing twelve months through Dec 2025 was -$38.3 million (up 28.14% YoY), and the annual figure for FY2025 was -$38.3 million, up 28.14%.
  • EBITDA for Q4 2025 was -$8.5 million at Rani Therapeutics Holdings, down from -$7.3 million in the prior quarter.
  • Over the last five years, EBITDA for RANI hit a ceiling of -$5.2 million in Q1 2021 and a floor of -$27.8 million in Q3 2021.
  • Median EBITDA over the past 5 years was -$13.6 million (2022), compared with a mean of -$13.6 million.
  • Biggest five-year swings in EBITDA: tumbled 882.7% in 2021 and later surged 42.94% in 2025.
  • Rani Therapeutics Holdings' EBITDA stood at -$13.4 million in 2021, then crashed by 30.83% to -$17.5 million in 2022, then increased by 23.16% to -$13.4 million in 2023, then dropped by 11.34% to -$15.0 million in 2024, then soared by 42.94% to -$8.5 million in 2025.
  • The last three reported values for EBITDA were -$8.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$10.5 million (Q2 2025) per Business Quant data.